Jingfeng Pharmaceutical (000908): medical sodium hyaluronate gel has been granted administrative license for the production of medical devices, and the R & D pipeline has been gradually realized.
Jingfeng Pharmaceutical (000908): the company's performance is expected to improve innovation pipeline harvest is expected.
Deepin* Company* Jingfeng Pharmaceutical (000908): The low point has passed, the inflection point is approaching
Jingfeng Pharmaceutical (000908) comment report: under the influence of policy and marketing reform, short-term performance is under pressure and long-term development prospects are not changed.
Jingfeng Pharmaceutical (000908) Review report: the United States has further enriched the product line of newly approved methylprednisolone tablets and bivalirudin for injection.
Jingfeng Pharmaceutical (000908): firmly promote the reform of the company and keep an open mind.
Jingfeng Pharmaceutical (000908): short-term income pressure looking forward to the results of sales reform
Jingfeng Pharmaceutical (000908): subsidiary Shangjin Zaitian 2019 is about to be harvested.
Jingfeng Pharmaceutical (000908): actively seek business opportunities in cooperation with CRO
Comments on Jingfeng Pharmaceutical (000908): the overseas business of the first batch of ANDA listing of US subsidiaries is progressing smoothly
景峰医药(000908)点评:剥离医院资产 聚焦药品主业
景峰医药(000908)点评报告:坚持走国际化高端特色仿创路线 渐入产品收获期
景峰医药(000908)季报点评:业绩稳健增长 产品线进一步丰富
景峰医药(000908):核心产品稳定增长 高研发投入助力公司转型升级
景峰医药(000908)半年报点评:主营业务增长良好 研发投入力度加大
景峰医药(000908):战略聚焦高端仿制药 持续并购整合升级制药版图
景峰医药(000908)公司首次覆盖报告:顺应行业大势 开启“仿制+创新”之门
景峰医药(000908)年报点评:业绩基本符合预期 战略布局值得期待
[Huili Securities (Hong Kong)] Jingfeng Medicine: elemene or another Jingfeng
景峰医药(000908):榄香烯增长空间巨大 17年营收拐点和估值提升预期
No Data
No Data